Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Orsay – page 188

3 415 clinical trials in Orsay, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Orsay at a glance
3 415
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 415 trials in Orsay

Open in trial search

Study on Cefoxitin and Sodium Chloride for Preventing Infections After Colorectal Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefoxitin Sodium
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Alport's syndrome

Not recruiting

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Vonafexor
  • Sponsor:ENYO Pharma

Study of Itolizumab with Corticosteroids for Initial Treatment of Acute Graft Versus Host Disease in Patients After Bone Marrow Transplant

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Itolizumab
  • Sponsor:Equillium Inc.

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Thymoma malignant

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Parkinson's disease

Not recruiting

Study of Radotinib safety and effectiveness compared to placebo in people with Parkinson's disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Radotinib Dihydrochloride
  • Sponsor:Il-Yang Pharm Co. Ltd.

Hypercholesterolaemia

Not recruiting

Study on the Safety and Efficacy of MK-0616 for Adults with High Cholesterol

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide Chloride
  • Sponsor:Merck Sharp & Dohme LLC

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Deafness

Not recruiting

Study on SENS-401 to Prevent Hearing Loss Caused by Cisplatin in Adults with Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:R-Azasetron Besilate
  • Sponsor:Sensorion

Study on Talazoparib for Maintenance Treatment in Patients with Advanced Malignant Pleural or Peritoneal Mesothelioma After Initial Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Talazoparib
  • Sponsor:Hospices Civils De Lyon

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Orsay

What the registry says about research in the country

01 Neurological Studies

Advanced research focusing on neurological disorders including innovative imaging studies for epilepsy, multiple sclerosis, and Huntington's disease. These trials utilize cutting-edge PET-MRI technology to better understand disease progression and treatment effectiveness.

  • Drug-resistant epilepsy imaging
  • Multiple sclerosis inflammation markers
  • Huntington's disease biomarkers

Research aims to improve diagnostic accuracy and treatment planning through advanced imaging techniques.

02 Psychiatric & Mental Health

Innovative studies exploring treatments for mental health conditions, with a focus on early psychosis and severe depression. Trials evaluate novel therapeutic approaches combining medication and digital interventions.

  • Early psychosis treatment
  • Ketamine therapy for depression
  • Personalized care approaches

Research emphasizes personalized treatment strategies and innovative therapeutic combinations.

03 Critical Care Medicine

Studies addressing critical care challenges including septic shock management and specialized treatments for severe medical conditions. Focus on improving patient outcomes in intensive care settings.

  • Septic shock delirium prevention
  • Severe hyponatremia management
  • Ventilator-associated pneumonia

Trials aim to enhance treatment protocols in critical care scenarios.

04 Oncology & Imaging

Advanced research in cancer treatment and diagnostic imaging, particularly focusing on colorectal cancer and CNS lymphoma. Studies utilize innovative imaging techniques for better disease characterization.

  • Colorectal cancer therapy
  • CNS lymphoma imaging
  • PET/MR imaging applications

Research combines cutting-edge imaging with targeted therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.